[go: up one dir, main page]

AU2001259271A1 - 14094, a novel human trypsin family member and uses thereof - Google Patents

14094, a novel human trypsin family member and uses thereof

Info

Publication number
AU2001259271A1
AU2001259271A1 AU2001259271A AU5927101A AU2001259271A1 AU 2001259271 A1 AU2001259271 A1 AU 2001259271A1 AU 2001259271 A AU2001259271 A AU 2001259271A AU 5927101 A AU5927101 A AU 5927101A AU 2001259271 A1 AU2001259271 A1 AU 2001259271A1
Authority
AU
Australia
Prior art keywords
family member
novel human
human trypsin
trypsin family
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259271A
Inventor
Kyle J. Macbeth
Rachel Meyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2001259271A1 publication Critical patent/AU2001259271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6427Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/57515
    • G01N33/5752
    • G01N33/57535
    • G01N33/57545
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001259271A 2000-04-28 2001-04-30 14094, a novel human trypsin family member and uses thereof Abandoned AU2001259271A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US20062100P 2000-04-28 2000-04-28
US60/200,621 2000-04-28
US60200621 2000-04-28
US63330000A 2000-08-08 2000-08-08
US09/633,300 2000-08-08
US09633300 2000-08-08
PCT/US2001/013903 WO2001083781A2 (en) 2000-04-28 2001-04-30 14094, a novel human trypsin family member and uses thereof

Publications (1)

Publication Number Publication Date
AU2001259271A1 true AU2001259271A1 (en) 2001-11-12

Family

ID=36613688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259271A Abandoned AU2001259271A1 (en) 2000-04-28 2001-04-30 14094, a novel human trypsin family member and uses thereof

Country Status (4)

Country Link
US (2) US7071004B1 (en)
EP (1) EP1280923A2 (en)
AU (1) AU2001259271A1 (en)
WO (1) WO2001083781A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20040111525A (en) * 2002-04-17 2004-12-31 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
WO2004099779A1 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3)
CN102580109B (en) * 2012-03-02 2013-11-06 河南师范大学 Anti-cancer drug carrier and method for producing same
US12391936B2 (en) 2017-03-17 2025-08-19 Rescue Hearing, Inc. Gene therapy systems and related methods for treatment of hearing loss
JP2020509786A (en) * 2017-03-17 2020-04-02 レスキュー ヒヤリング インコーポレイテッド Gene therapy compositions and methods for the treatment of hearing loss
TW202019955A (en) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (en) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH0745265B2 (en) * 1989-04-07 1995-05-17 日本製紙株式会社 Thermal recording paper
ATE155813T1 (en) * 1989-05-19 1997-08-15 Genentech Inc HER2 EXTRACELLULAR DOMAIN
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ATE207958T1 (en) * 1989-08-04 2001-11-15 Schering Ag EXTERNAL DOMAIN OF C-ERBB-2:GP75
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5464751A (en) * 1990-04-06 1995-11-07 Trustees Of The University Of Pennsylvania Ligand for the neu gene product
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
AU643109B2 (en) * 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) * 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
FI941572L (en) * 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
US5326069A (en) * 1992-10-28 1994-07-05 Burton Mechanical Contractors, Inc. Vacuum toilet system and discharge valve thereof
ATE295420T1 (en) * 1992-02-06 2005-05-15 Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5355594A (en) * 1992-10-09 1994-05-09 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5837523A (en) * 1994-05-05 1998-11-17 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
CA2245835A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5882864A (en) * 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
PT1864999E (en) * 1996-11-27 2009-06-25 Genentech Inc Affinity purification of polypeptide on protein a matrix
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
US20020076695A1 (en) * 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
US5994071A (en) * 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1490386B1 (en) * 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
EP1064027B1 (en) * 1998-03-27 2008-06-18 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
CN1305896C (en) * 1998-05-06 2007-03-21 基因技术股份有限公司 Protein purification by ion exchange chromatography
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
ATE425749T1 (en) * 1999-01-27 2009-04-15 Cornell Res Foundation Inc TREATMENT OF HER-2/NEW OVEREXPRESSION-ASSOCIATED CANCER
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
EP1263948A2 (en) * 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP2002543777A (en) * 1999-05-07 2002-12-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Serine protease
AU5638400A (en) * 1999-06-23 2001-01-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
DE60042693D1 (en) * 1999-08-27 2009-09-17 Genentech Inc DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AU2001233262A1 (en) * 2000-02-03 2001-08-14 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001074897A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Protein amf-1 to amf-10 and nucleic acids encoding the same
JP2004512022A (en) * 2000-06-09 2004-04-22 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of colon cancer
JP2004501637A (en) * 2000-06-26 2004-01-22 スージェン・インコーポレーテッド New protease
EP1379686B1 (en) * 2000-12-01 2012-09-05 Response Genetics, Inc. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates

Also Published As

Publication number Publication date
EP1280923A2 (en) 2003-02-05
US7071004B1 (en) 2006-07-04
WO2001083781A3 (en) 2002-07-11
WO2001083781A2 (en) 2001-11-08
US20070009433A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
AU2001263360A1 (en) 50365, a hexokinase family member and uses thereof
AU2001261572A1 (en) 38594, a novel human transporter and uses thereof
AU2001268561A1 (en) 22109, a novel human thioredoxin family member and uses thereof
AU2001271732A1 (en) 25869, a human carboxylesterase and uses thereof
AU2001259271A1 (en) 14094, a novel human trypsin family member and uses thereof
AU2001291235A1 (en) 22108 and 47916, novel human thioredoxin family members and uses thereof
AU2001257594A1 (en) 21953, a novel human prolyl oligopeptidase family member and uses thereof
AU2001275310A1 (en) 46980, a novel human neuroligin family member and uses thereof
AU2001259191A1 (en) 25692, a novel human o-methyltransferase family member and uses thereof
AU2001288606A1 (en) 8797, a human galactosyltransferase and uses thereof
AU2001249700A1 (en) 33167, a novel human hydrolase and uses therefor
AU2001243447A1 (en) 16835, a human phospholipase c and uses thereof
AU2001263233A1 (en) 57805, a novel human cadherin family member and uses thereof
AU2001291221A1 (en) 55063, a human nmda family member and uses thereof
AU2001243438A1 (en) 23436, a human ubiquitin protease family member and uses thereof
AU2002232644A1 (en) 53010, a human carboxylesterase family member and uses thereof
AU2001268570A1 (en) 33358, a novel human ankyrin family member and uses thereof
AU2001241770A1 (en) 18036, a novel calpain-like protease and uses thereof
AU2001274921A1 (en) 46745, a novel human acyltransferase family member and uses thereof
AU2001293046A1 (en) M32404, a novel human trypsin and uses thereof
AU2001261651A1 (en) 33428, a novel human metalloprotease family member and uses thereof
AU2001291135A1 (en) 63760, a novel human transporter and uses thereof
AU2001249697A1 (en) 32449, a novel human transporter and uses thereof
AU2001249456A1 (en) 46743 and 27417, novel human acyltransferase family members and uses therefor
AU2001261798A1 (en) 26493, a novel human must dgtpase family member and uses thereof